Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;130(6):750-753.
doi: 10.1111/bju.15896. Epub 2022 Sep 30.

The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

Affiliations

The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

Hans Veerman et al. BJU Int. 2022 Dec.
No abstract available

Keywords: #PCSM; #ProstateCancer; #uroonc; PSMA negative; biochemical recurrence; oncological outcomes; positron emission tomography/computed tomography; prostate cancer; prostate-specific membrane antigen; robot-assisted radical prostatectomy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves with separate lines for patients with non‐PSMAPET‐expressing and PSMAPET‐expressing PCa showing BCR‐free survival.

References

    1. Veerman H, Donswijk M, Bekers E et al. The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography. BJU Int 2022; 129: 314–7 - PMC - PubMed
    1. Crocerossa F, Marchioni M, Novara G et al. Detection rate of prostate specific membrane antigen tracers for positron emission tomography/Computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta‐analysis. J Urol 2021; 205: 356–69 - PubMed
    1. Eiber M, Herrmann K, Calais J et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA‐ligand PET/CT. J Nucl Med 2018; 59: 469–78 - PubMed
    1. Ceci F, Oprea‐Lager DE, Emmett L et al. E‐PSMA: the EANM standardized reporting guidelines v1.0 for PSMA‐PET. Eur J Nucl Med Mol Imaging 2021; 48: 1626–38 - PMC - PubMed
    1. Bronsert P, Reichel K, Ruf J. Loss of PSMA expression in non‐neuroendocrine dedifferentiated acinar prostate cancer. Clin Nucl Med 2018; 43: 526–8 - PubMed

MeSH terms

Substances